Italian clinical research in non-small-cell lung cancer

Vittorio Gebbia; null Nicolella; Vittorio Gebbia; Antonio Rossi; Galetta Galetta; null Galetta; null Galetta; null Colantuoni; Paolo Maione; Ciro Guerriero; Domenico Galetta; null Colucci; Cesare Gridelli; Carmine Ferrara; Filomena Del Gaizo

Italian clinical research in non-small-cell lung cancer

Vittorio Gebbia, Nicolella, Vittorio Gebbia, Antonio Rossi, Galetta Galetta, Galetta, Galetta, Colantuoni, Paolo Maione, Ciro Guerriero, Domenico Galetta, Colucci, Cesare Gridelli, Carmine Ferrara, Filomena Del Gaizo

Promozione della Salute, Materno-Infantile, di Medicina Interna e Specialistica di Eccellenza “G. D’Alessandro”

Risultato della ricerca: Article › peer review

4 Citazioni (Scopus)

Abstract

Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC

Lingua originale	English
pagine (da-a)	110-115
Numero di pagine	6
Rivista	Annals of Oncology
Volume	16
Stato di pubblicazione	Published - 2005

All Science Journal Classification (ASJC) codes

???subjectarea.asjc.2700.2720???
???subjectarea.asjc.2700.2730???

Altri file e collegamenti

OA Link

Cita questo

@article{8392a7993d774e598d0cdd7225c9eeaf,

title = "Italian clinical research in non-small-cell lung cancer",

abstract = "Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC",

author = "Vittorio Gebbia and Nicolella and Vittorio Gebbia and Antonio Rossi and Galetta Galetta and Galetta and Galetta and Colantuoni and Paolo Maione and Ciro Guerriero and Domenico Galetta and Colucci and Cesare Gridelli and Carmine Ferrara and {Del Gaizo}, Filomena",

year = "2005",

language = "English",

volume = "16",

pages = "110--115",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Italian clinical research in non-small-cell lung cancer

AU - Gebbia, Vittorio

AU - Nicolella, null

AU - Gebbia, Vittorio

AU - Rossi, Antonio

AU - Galetta, Galetta

AU - Galetta, null

AU - Colantuoni, null

AU - Maione, Paolo

AU - Guerriero, Ciro

AU - Galetta, Domenico

AU - Colucci, null

AU - Gridelli, Cesare

AU - Ferrara, Carmine

AU - Del Gaizo, Filomena

PY - 2005

Y1 - 2005

N2 - Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC

AB - Lung cancer is the most common cause of cancer deaths in both men and women worldwide and has a poor prognosis. Non-small-cell lung cancer (NSCLC) represents approximately 80% of all lung cancers. Surgery is the only curative treatment of NSCLC but only 15-20% of tumours can be radically resected with a survival of about 40% at 5 years. Considering these disappointing results NSCLC is one of the most frequent subjects of clinical research worldwide. Italy is playing an important role in the clinical research of NSCLC performing phase I, II and III trials, prevalently by cooperative groups, and achieving important results that contributed to define the standard treatment for NSCLC patients. In particular, Italy is leader in the clinical research of the treatment of advanced NSCLC elderly patients. Today, large controlled clinical trials are ongoing. In this paper we analyse and discuss the main trials performed by Italian groups in the fields of NSCLC

UR - http://hdl.handle.net/10447/33078

M3 - Article

SN - 0923-7534

VL - 16

SP - 110

EP - 115

JO - Annals of Oncology

JF - Annals of Oncology

ER -

Italian clinical research in non-small-cell lung cancer

Abstract

All Science Journal Classification (ASJC) codes

Altri file e collegamenti

Fingerprint

Cita questo